Form 4 for WVE Wave Life Sciences, Inc.
Accepted 2024-10-11 00:00:00 ET · period of report 2024-10-11 · accession 0000950170-24-114422 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-10-11 | 2024-10-11 | WVE | Moran Kyle | CFO | M - OptEx | $2.48 | +25.0K | 44.8K | +126% | +$62.0K |
| D | 2024-10-11 | 2024-10-11 | WVE | Moran Kyle | CFO | M - OptEx | $0.00 | -25.0K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2024-10-11 | M | A | 25,000 | $2.48 | 44,777 | D | — | — | |
| 2 | Derivative | Share Option (right to buy) | 2024-10-11 | M | D | 25,000 | $0.00 | 0 | D | $2.48 · — to 2025-03-10 | 25,000 Ordinary Shares | (F1) The share options that were exercised via cash purchase in this reportable transaction were fully vested. |